Current status of pharmacotherapy against metastatic renal cell carcinoma in Japan
Author:
Publisher
Wiley
Subject
Urology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1442-2042.2012.02962.x/fullpdf
Reference65 articles.
1. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma;Motzer;J. Clin. Oncol.,1999
2. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma;Motzer;J. Clin. Oncol.,2002
3. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study;Heng;J. Clin. Oncol.,2009
4. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients;Naito;Eur. Urol.,2010
5. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma;Patil;Ann. Oncol.,2011
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era;Urologic Oncology: Seminars and Original Investigations;2021-01
2. Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data;Japanese Journal of Clinical Oncology;2020-12-15
3. Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis;BMC Cancer;2019-07-15
4. Efficacy and safety of axitinib in elderly patients with metastatic renal cell carcinoma;Medical Oncology;2016-07-21
5. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma;Clinical Genitourinary Cancer;2016-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3